| Literature DB >> 32309576 |
Garth L Nicolson1, Steven Rosenblatt2, Gonzalo Ferreira de Mattos3, Robert Settineri4, Paul C Breeding5, Rita R Ellithorpe6, Michael E Ash7.
Abstract
Membrane Lipid Replacement is the use of functional oral supplements containing cell membrane glycerolphospholipids and antioxidants to safely replace damaged membrane lipids that accumulate during aging and in various chronic and acute diseases. Most if not all clinical conditions and aging are characterized by membrane phospholipid oxidative damage, resulting in loss of membrane and cellular function. Clinical trials have shown the benefits of Membrane Lipid Replacement supplements in replenishing damaged membrane lipids and restoring mitochondrial function, resulting in reductions in fatigue in aged subjects and patients with a variety of clinical diagnoses. Recent observations have indicated that Membrane Lipid Replacement can be a useful natural supplement strategy in a variety of conditions: chronic fatigue, such as found in many diseases and disorders; fatiguing illnesses (fibromyalgia and chronic fatigue syndrome); chronic infections (Lyme disease and mycoplasmal infections); cardiovascular diseases; obesity, metabolic syndrome and diabetes; neurodegenerative diseases (Alzheimer's disease); neurobehavioral diseases (autism spectrum disorders); fertility diseases; chemical contamination (Gulf War illnesses); and cancers (breast, colorectal and other cancers). Membrane Lipid Replacement provides general membrane nutritional support during aging and illness to improve membrane function and overall health without risk of adverse effects.Entities:
Keywords: Membrane phospholipids; aging; cancer; cardiovascular diseases; chemical contamination; chronic diseases; chronic infections; clinical trials; diabetes; fatigue; fertility; lipid oxidation; metabolic diseases; metabolic syndrome; mitochondrial function; neurobehavioral diseases; neurodegenerative diseases; obesity
Year: 2016 PMID: 32309576 PMCID: PMC6941554 DOI: 10.15190/d.2016.1
Source DB: PubMed Journal: Discoveries (Craiova) ISSN: 2359-7232
Clinical trials and effects of NTFactor® MLR supplements on fatigue scores.
aModified from Nicolson[3]; bPiper Fatigue Scale[43]; cAdvanced Physician’s Formula with NTFactor®; §p<0.0001, *p<0.001 t-test with/without NTFactor®; Av. - Average; CFS - chronic fatigue syndrome; ME - myalgic encephalomyelitis; GW – Gulf War;
| MLR Supplment | Subjects/patients | No. of patients | Av. age Time (weeks) | Reduction (%)b | Reference |
|---|---|---|---|---|---|
| Propax/ NTFactor® | Chronic fatigue | 34 | 50.3 | 40.5 § | Ellithorpe et al.[ |
| NTFactor® | Aging, chronic fatigue | 22 | 68.9 | 35.5 * | Agadjanyan et al.[ |
| NTFactor® | CFS/fibromyalgia | 15 | 44.8 | 43.1 * | Nicolson & Ellithorpe[ |
| Healthy Curb® | Obesity, fatigue | 35 | 42 | 23.9 * | Ellithrope et al.[ |
| APF/ NTFactor®c | Aging, chronic fatigue | 67 | 57.3 | 36.8 § | Nicolson et al.[ |
| Propax/ NTFactor® | Cancer, fatigue | 35 | 50.7 | 30.1 * | Nicolson[ |
| ATP Fuel®/ NTFactor® | CFS/ME | 30 | 55 | 30.7 § | Nicolson et al.[ |
| ATP Fuel®/ NTFactor® GW | GW Illness, fatigue | 16 | 42.2 | 34.6 * | Nicolson et al.[ |
| ATP Fuel®/ NTFactor® | Lyme disease, fatigue | 17 | 52.4 | 26.0 * | Nicolson et al.[ |
Suggested Doses, Current and Potential Uses of Oral MLR Supplements
aDose range in grams per day based on weight of NTFactor Lipids®bNTFactor® or NTFactor Lipids®; CD – cardiovascular disease; CFS/ME – chronic fatigue syndrome/myalgic encephalomyelitis; GW – Gulf War; MetSyn – metabolic syndrome;
| Use | Subjects/patients | Age group | MLR Lipid Supplement | NTFL Dosea range (g/day) | Reference |
|---|---|---|---|---|---|
| General health | Aged | senior | NTFactor/Lb | 2-3 | Ellithorpe et al.[ |
| Fatigue | Aged | senior | NTFactor/L | 2-3 | Agadjanyan et al.[ |
| Fatigue | CFS/ME | adult/teen | NTFactor/L | 2-4 | Nicolson & Ellithorpe[ |
| Fatigue | CFS/ME | adult | ATP Fuel | 4 | Nicolson et al.[ |
| Fatigue | Fibromyalgia | adult | NTFactor/L | 3-4 | Nicolson & Ellithorpe[ |
| Weight loss | Obesity, fatigue | adult | NTFactor | 1-3 | Ellithrope et al.[ |
| General health | Neurodegenerative Dis. | adult | NTFactor/L | 3-4 | Nicolson et al.[ |
| CD health | CD risk/CD disease | adult | NTFactor/L | 2-4 | Ellithorpe et al.[ |
| Metabolic health | MetSyn/diabetes | adult | NTFactor/L | 2-4 | Nicolson[ |
| Metabolic health | Diabetes | adult | ATP Fuel | 4 | Nicolson et al.[ |
| Neurobehavior | Autism Spectrum Dis. | child | NTFactor/L | 1-2 | Nicolson et al.[ |
| Infections | Lyme/mycoplasma | adult | ATP Fuel | 4 | Nicolson et al.[ |
| Fertility | Fertility Diseases | adult | NTFactor/L | 2-3 | - |
| Fatigue | Cancer | adult | NTFactor/L | 2-3 | Nicolson and Conklin[ |
| Anemia | Anemia | adult | NTFactor/L | 1-2 | Ellithorpe et al.[ |
| Injury | Spinal injury | adult | NTFactor/L | 1-2 | Ellithorpe et al.[ |
| Autoimmune | Rheumatoid arthritis | adult | ATP Fuel | 4 | Nicolson et al.[ |
| General health | Pregnancy | adult | NTFactor/L | 1-2 | Ellithorpe et al.[ |
| Chemical detox | GW Illnesses | adult | NTFactor/L | >4 | Nicolson et al.[ |
| Mental clarity | Aging | adult | NTFactor L | 1-2 | Ellithorpe et al.[ |